NTP Formal Name Pattern

No part of the NTP description will be capitalized (with the exception of the “L” as a symbol/abbreviation for “litre” and as in “mL” for millilitre, and for capitalization of single letters as appropriate in a substance name (e.g., penicillin G, abobotulinumtoxinA);
TALLman lettering will not be used;
Waters of hydration will not be described in NTP substance names (see Appendix C, Hydration and Solvation)

Formal Naming Pattern for Single Active Ingredient Substance NTPs

The following pattern will be used for products with a single active ingredient substance:

<<Basis of Strength Substance (Precise ingredient substance*)>> <<Strength value and unit of measure>> <<Dose Form>> <<Unit of presentation*>>

*included only if required

The following table gives the components required to build a single ingredient NTP formal name, as well as the corresponding NTP formal name:

Basis of Strength Substance (BoSS)	Precise Ingredient Substance	Strength	Dose form	Unit of presentation	NTP_Formal_Name
levothyroxine sodium	same as BoSS	25 mcg	oral tablet	not explicitly stated	levothyroxine sodium 25 mcg oral tablet
levothyroxine sodium	same as BoSS	500 mcg per vial	powder for solution for injection	not required – stated as part of strength (vial)	levothyroxine sodium 500 mcg per vial powder for solution for injection
atorvastatin	(atorvastatin calcium)	20 mg	oral tablet	not explicitly stated	atorvastatin (atorvastatin calcium) 20 mg oral tablet
naproxen	(naproxen, naproxen sodium)*	200 mg	oral capsule	not explicitly stated	naproxen (naproxen, naproxen sodium) 200 mg oral capsule
metoclopramide hydrochloride	same as BoSS	10 mg per 2 mL	solution for injection	vial	metoclopramide hydrochloride 10 mg per 2 mL solution for injection vial

*If two forms of an active ingredient constitute the precise active ingredient, they will be in alpha-order separated by a comma within a single set of brackets

Formal Naming Pattern for Multiple Active Ingredient Substance NTPs

The early versions of the Canadian Clinical Drug Data Set will exclude products with greater than 5 active ingredients. The following pattern will be used for products with multiple ingredient substances:

<<Basis of Strength Substance A (Precise ingredient substance A)*>> <<Strength value and unit of measure>> <<and>> <<Basis of Strength Substance B (Precise ingredient substance B*) >> <<Strength value and unit of measure>> <<Dose Form>> <<Unit of presentation*>>

*included only if required

The following table gives the components required to build a multi-ingredient NTP formal name, as well as the corresponding NTP formal name:

Basis of Strength Substance	Precise Ingredient Substance		Strength	Dose form	Unit of presentation	NTP_Formal_Name
amlodipine and atorvastatin	(amlodipine besylate) (atorvastatin calcium)		10 mg 20 mg	oral tablet	not explicitly stated	amlodipine (amlodipine besylate) 10 mg and atorvastatin (atorvastatin calcium) 20 mg oral tablet
formoterol fumarate and mometasone furoate	same as BoSS		5 mcg per actuation 200 mcg per actuation	pressurised inhalation	not required – stated as part of strength (actuation)	formoterol fumarate 5 mcg per actuation and mometasone furoate 200 mcg per actuation pressurised inhalation
piperacillin and tazobactam		(piperacillin sodium) (tazobactam sodium)	4 g per vial 0.5 g per vial	powder for solution for injection	not required – stated as part of strength (vial)	piperacillin (piperacillin sodium) 4 g per vial and tazobactam (tazobactam sodium) 0.5 g per vial powder for solution for injection
sulfamethoxazole and trimethoprim		same as BoSS same as BoSS	400 mg per 5 mL 80 mg per 5 mL	solution for injection	ampoule	sulfamethoxazole 400 mg per 5 mL and trimethoprim 80 mg per 5 mL solution for injection ampoule

The following rules will be applied to all multi-ingredient NTPs:

“and” will be used as the conjunction between active ingredient substances/strengths;

The order of active ingredient substances in a multi-ingredient NTP will be alphabetical for the formal name; the order of active substances in the French description will follow the order for the corresponding English ingredient names, and therefore ingredients might not appear in alphabetical order in French within multi-ingredient NTPs.